NRAS and acute myeloid leukemia: Similarly, NRAS mutant pCMML had the shortest AML-FS (16 months; p = 0.0001) versus other subtypes combined (AML-FS 29 months) and individually (Fig. 1F and Supplementary Fig. 1E).